Grifols, S.A. (GRFS)
Healthcare • Drug Manufacturers - General
StockNasdaqGSSpainUS3984384087
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Grifols, S.A., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 12 Nov 2026 20:15. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 25 Feb 2027 16:00 | — | — | — | Upcoming |
| 27 Jul 2026 20:00 | 0.28 | 0.17 | -40.1% | Miss |
| 28 Jul 2025 18:00 | 0.28 | 0.22 | -19.2% | Miss |
| 30 Jul 2024 14:00 | 0.23 | 0.15 | -32.6% | Miss |
| 27 Jul 2023 08:00 | 0.15 | 0.10 | -30.5% | Miss |
| 29 Jul 2021 08:00 | 0.27 | 0.28 | +3.2% | Beat |
| 26 Feb 2021 18:00 | 0.25 | 0.29 | +15.8% | Beat |
| 05 Nov 2020 02:00 | 0.35 | 0.37 | +6.7% | Beat |
| 30 Jul 2020 08:00 | 0.37 | 0.36 | -1.3% | Miss |
| 21 Apr 2020 08:00 | 0.30 | 0.24 | -18.6% | Miss |
| 27 Feb 2020 15:00 | 0.31 | 0.31 | -1.6% | Miss |
| 29 Oct 2019 03:00 | 0.30 | 0.28 | -7.1% | Miss |
| 31 Jul 2019 03:00 | 0.32 | 0.33 | +0.1% | In line |
| 07 May 2019 05:00 | 0.25 | 0.25 | -1.3% | Miss |
| 28 Feb 2019 02:00 | 0.31 | 0.24 | -22.9% | Miss |
| 05 Nov 2018 05:00 | 0.31 | 0.29 | -5.8% | Miss |
| 27 Jul 2018 02:00 | 0.32 | 0.34 | +6.7% | Beat |
| 03 May 2018 02:00 | 0.29 | 0.28 | -3.8% | Miss |
| 28 Feb 2018 03:00 | 0.31 | 0.29 | -8.1% | Miss |
| 02 Nov 2017 03:00 | 0.30 | 0.28 | -4.3% | Miss |
| 28 Jul 2017 03:00 | 0.28 | 0.28 | +1.5% | Beat |
| 03 May 2017 02:00 | 0.26 | 0.27 | +1.7% | Beat |
| 28 Feb 2017 02:00 | 0.25 | 0.25 | +3.6% | Beat |
| 08 Nov 2016 02:00 | 0.25 | 0.28 | +11.6% | Beat |
| 28 Jul 2016 03:00 | 0.27 | 0.26 | -5.5% | Miss |
| 05 May 2016 03:00 | 0.24 | 0.23 | -4.2% | Miss |
| 29 Feb 2016 03:00 | 0.27 | 0.24 | -11.5% | Miss |
| 04 Nov 2015 06:00 | 0.22 | 0.26 | +16.0% | Beat |
| 30 Jul 2015 01:00 | 0.23 | 0.24 | +6.9% | Beat |
| 07 May 2015 06:00 | 0.24 | 0.25 | +5.5% | Beat |
| 26 Feb 2015 08:00 | 0.28 | 0.17 | -41.0% | Miss |
| 04 Nov 2014 02:00 | 0.27 | 0.27 | -1.3% | Miss |
| 31 Jul 2014 01:00 | 0.30 | 0.28 | -8.1% | Miss |
| 06 May 2014 16:00 | 0.28 | 0.30 | +6.4% | Beat |
Annual results · EUR
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 7.5B | +4.3% | 402M | 5.3% | 0.59 | +156.5% | 624M |
| 2024 | 7.2B | +9.4% | 157M | 2.2% | 0.23 | +155.6% | 530M |
| 2023 | 6.6B | +8.7% | 42M | 0.6% | 0.09 | -71.0% | -93M |
| 2022 | 6.1B | — | 185M | 3.1% | 0.31 | — | -394.3M |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| Nov 2026 In progress | 8.30 | 8.89 | 8.25 | 8.77 | +8.21% | 8,064,186 | |
| Oct 2026 | 7.29 | 8.30 | 7.15 | 8.10 | +10.81% | 13,166,800 | |
| Sep 2026 | 7.74 | 7.99 | 7.15 | 7.31 | -5.31% | 12,924,200 | |
| Aug 2026 | 7.90 | 8.38 | 7.65 | 7.72 | -1.91% | 8,196,000 | |
| Jul 2026 | 7.10 | 8.37 | 6.96 | 7.87 | +11.16% | 19,044,900 | 0.0940 |
| Jun 2026 | 7.86 | 7.93 | 7.06 | 7.08 | -9.81% | 13,447,400 | |
| May 2026 | 8.23 | 8.47 | 7.50 | 7.85 | -4.73% | 11,685,800 | |
| Apr 2026 | 8.12 | 8.83 | 7.86 | 8.24 | +2.74% | 15,966,300 | |
| Mar 2026 | 8.91 | 9.11 | 7.39 | 8.02 | -11.87% | 18,490,100 | |
| Feb 2026 | 9.28 | 9.77 | 8.28 | 9.10 | -1.62% | 11,778,100 | |
| 51 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Grifols (BME:GRF) Stock Price Trails Q3 Results As Debt Questions Linger (opens in a new tab) Simply Wall St. · 03 Nov 2026 19:11
- Grifols Beats Q3 Revenue Forecasts as Immunoglobulin Demand Supports Profit Growth (opens in a new tab) InvestorsHub · 03 Nov 2026 11:17
- Grifols SA (GRFS) Q3 2026 Earnings Call Highlights: Biopharma Growth Accelerates as Margin ... (opens in a new tab) GuruFocus.com · 03 Nov 2026 05:03
- Grifols (GRFS) Q3 2026 Earnings Call Transcript (opens in a new tab) Motley Fool · 03 Nov 2026 03:58
- Grifols Q3 Earnings Call Highlights (opens in a new tab) MarketBeat · 02 Nov 2026 20:12
- Grifols Q3 revenue exceeds estimates as immunoglobulin sales drive growth (opens in a new tab) Investing.com · 02 Nov 2026 18:20
- Grifols (BME:GRF) Stock Still Looks Cheap Based On Current Earnings (opens in a new tab) Simply Wall St. · 27 Oct 2026 06:07
- Plasma Demand Supports Grifols, S.A.’s (GRFS) Path Back to Financial Strength (opens in a new tab) Insider Monkey · 23 Oct 2026 15:35
- Can Ambu (CPSE:AMBU B) Look Undervalued As Board Changes Put Governance In Focus? (opens in a new tab) Simply Wall St. · 11 Oct 2026 13:15
- Are Options Traders Betting on a Big Move in Grifols Stock? (opens in a new tab) Zacks · 07 Oct 2026 13:54
- Grifols (BME:GRF) Stock May Be Below Fair Value On Earnings (opens in a new tab) Simply Wall St. · 26 Sep 2026 16:14
- GRFS vs. SDZNY: Which Stock Should Value Investors Buy Now? (opens in a new tab) Zacks · 24 Sep 2026 15:40
- GRFS or SDZNY: Which Is the Better Value Stock Right Now? (opens in a new tab) Zacks · 08 Sep 2026 16:40
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 8.84 USD
- Market cap
- 6.0B
- Dividend yield
- 1.24%
- 5-year average yield
- 2.14%
- Payout ratio
- 13%
- Last dividend
- 0.0940 USD · 02 Jul 2026
- Exchange
- NasdaqGS
- Country
- Spain
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Currency
- USD
Dividends
| Ex-dividend date | Per share |
|---|---|
| 02 Jul 2026 | 0.0940 USD |
| 12 Aug 2025 | 0.1730 USD |
| 03 Jun 2021 | 0.4560 USD |
| 30 Oct 2020 | 0.2010 USD |
| 8 older dividends: create a free account to see them | |
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Yield Dividends per year as a share of today's price. Very high yields count for less: they often signal trouble. | 5.2 / 25 |
|
| Dividend safety Can the company keep paying? The dividend against free cash flow and earnings, plus debt and interest cover. | 5.3 / 25 |
|
| Dividend growth How many years in a row the dividend has risen, and how fast. | 1.9 / 15 |
|
| Quality Return on equity, net margin and how stable the margins are. | 6.5 / 15 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 7.7 / 10 |
|
| Analysts How far the analysts' average target is from today's price. | 4.7 / 5 |
|
- Score capped at 50: the dividend was cut recently
- Heavy debt: net debt is 5.0× EBITDA
- The dividend paid in the last 12 months is lower than in the 12 before
Income profile: it pays a dividend, so it is scored mainly on the dividend and how safe it is. Based on 95% of the figures (grade A). Warnings take 12 points off.
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 10.6× | Good | 30.56× |
| P/E (forward) | 7.07× | Good | 14.16× |
| Price / book | 1.84× | Fair | 3.5× |
| Price / sales | 0.79× | Good | 3.33× |
| EV / EBITDA | 13.39× | Fair | 11.19× |
| Free cash flow yield | 3.2% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 38.2% | Fair | 54.9% |
| Operating margin | 18.9% | Good | 5.8% |
| Net margin | 6.4% | Fair | 1.2% |
| Return on equity | 7.3% | Weak | 4.4% |
| Return on assets | 4.5% | Fair | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 7.5% | Fair | 10.1% |
| EPS growth / year | 23.9% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 1.12× | Fair | 0.4× |
| Net debt / EBITDA | 5.04× | Weak | 1.46× |
| Interest cover | 2.17× | Weak | 2.17× |
| Current ratio | 2.33× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 12.7% | Good | 0% |
| Payout of free cash flow | 65.8% | Fair | 28.7% |
| Payout of free cash flow (3 years) | 12.2% | Good | — |
| Dividend growth / year | 2% | Fair | 6.5% |
| Years of rising dividends | 0 | Weak | 1.5 |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow GRFS and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.